Evaluation of Doxil as First-Line Therapy of Advanced or Recurrent Endometrial Carcinoma
- Determine the antitumor activity and safety of doxorubicin HCl liposome in patients
with advanced or recurrent endometrial cancer.
- Determine the response rate, response duration, and overall survival of these patients
treated with this regimen.
OUTLINE: Patients receive doxorubicin HCl liposome IV over 1 hour. Courses repeat every 4
weeks in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years and then every 6 months for 3 years.
PROJECTED ACCRUAL: A total of 19-51 patients will be accrued for this study.
Primary Purpose: Treatment
Howard D. Homesley, MD
Gynecologic Oncology Network
United States: Federal Government
|Chao Family Comprehensive Cancer Center||Orange, California 92868|
|Indiana University Cancer Center||Indianapolis, Indiana 46202-5265|
|University of Mississippi Medical Center||Jackson, Mississippi 39216-4505|
|Washington University School of Medicine||Saint Louis, Missouri 63110|
|Duke Comprehensive Cancer Center||Durham, North Carolina 27710|
|Arthur G. James Cancer Hospital - Ohio State University||Columbus, Ohio 43210|
|New England Medical Center Hospital||Boston, Massachusetts 02111|
|Comprehensive Cancer Center at Wake Forest University||Winston-Salem, North Carolina 27157-1082|
|Brookview Research, Inc.||Nashville, Tennessee 37203|
|Holden Comprehensive Cancer Center||Iowa City, Iowa 52242-1009|